Navigation Links
Topiramate Exposure and Birth Defect Data to be Presented at the 29th International Epilepsy Congress
Date:7/20/2011

A(3)Columbia Comprehensive Epilepsy Center, New York, United States, (2)Emory University, Atlanta, United States, (3)Wolters Kluwer Pharma Solutions, Yardley, United States
Poster Session: Late Submissions
Poster #: 866
Time: 1:00-2:30 local time

About QNEXA Controlled Release CapsulesQNEXA [kyoo-nek-suh] is an investigational drug candidate being developed to address weight loss, type 2 diabetes and obstructive sleep apnea. QNEXA is a once-a-day, proprietary, oral, controlled-release formulation of low-dose phentermine and topiramate, which is designed to decrease appetite and increase satiety (the sense of feeling full), the two main mechanisms that impact eating behavior. In phase 2 and 3 clinical data to date, patients taking QNEXA have demonstrated statistically significant weight loss, glycemic control, and improvement in cardiovascular risk factors, when used in combination with a diet and lifestyle modification program.

About VIVUS VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead investigational product in clinical development, QNEXA®, has completed phase 3 clinical trials for the treatment of obesity and is currently being considered for approval by US and EU regulators. VIVUS received a Complete Response Letter, or CRL, to the initial QNEXA NDA on October 28, 2010. QNEXA is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS has submitted an NDA for avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. For more information about the company, please visit www.vivus.com.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use o
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Spherics, Inc. Announces Reduced Cognitive Impairment of Novel Extended Release Topiramate (SRx-502) as Compared to Topamax(R)
2. Upsher-Smith Laboratories Announces Initiation of Phase III Clinical Trial of USL255 (Extended-Release Topiramate) for Adjunctive Treatment of Partial-Onset Epilepsy
3. Upsher-Smith Laboratories Announces Initiation of Open-Label Extension Study of USL255 (Extended-Release Topiramate) for Adjunctive Treatment of Partial-Onset Epilepsy
4. Data Suggests Positive Pharmacokinetic Results From Phase I Research of Extended-Release Topiramate
5. FDA: Risk of Oral Birth Defects in Children Born to Mothers Taking Topiramate
6. Phase I Research of Extended-Release Topiramate Shows Less Fluctuation in Plasma Levels
7. Vaccine Study in New England Journal of Medicine Wrong in Concluding Mercury Exposures are Harmless, States SafeMinds
8. Dynavax Begins TOLAMBA(TM) Environmental Exposure Chamber Study
9. HIV Prevention Expert Dr. Timothy Mastro Speaks on Future of Pre-Exposure Prophylaxis at International AIDS Conference
10. New AVAC Report on Pre-Exposure Prophylaxis Calls for Immediate Planning to Anticipate Study Results of Potential New HIV Prevention Option
11. Two New Clinical Studies Show That Limited Exposure to Blood Transfusion Significantly Increases Morbidity and Mortality After Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... July 25, 2014 /PRNewswire-iReach/ -- Dr. Michael Gabriel ... Pediatrics, reacts to a recent study, which shows how grief ... - http://photos.prnewswire.com/prnh/20140723/129709 According to ... stress are more likely than others to grow up overweight ... There were two specific types of stress that ...
(Date:7/24/2014)... , July 24, 2014   AcelRx Pharmaceuticals, ... company focused on the development and commercialization of innovative ... today confirmed the PDUFA date for Zalviso remains July ... a rumor circulated online stating the Food and Drug ... 2014 there has been no notification to the company ...
(Date:7/24/2014)... , July 24, 2014  Parnell Pharmaceuticals Holdings ... that will be added to Parnell,s already extensive ... Pty Ltd, a biotechnology company. The compounds now ... shown promise in bone regeneration and dermal regeneration, ... the compounds for the veterinary market with the ...
Breaking Medicine Technology:Dr. Michael Gabriel of GPM Pediatrics, a Noted Staten Island Pediatrics Clinic, Comments on Study, Which Names Grief as a Cause of Obesity in Children 2AcelRx Pharmaceuticals Confirms July 27, 2014 PDUFA Date for Zalviso 2Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 2Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 3Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 4
... OXIS International, Inc. (OTC Bulletin Board: OXIS ... named former Wal-Mart executive Ken Eaton to its Board ... including three independent Directors. "I am very ... the OXIS International Board of Directors," said Anthony J. ...
... June 27, 2011 Pacira Pharmaceuticals, Inc ., ... company, today announced that it has been included in ... its comprehensive set of U.S. and global equity indexes ... 3000 Index measures the performance of the 3,000 largest ...
Cached Medicine Technology:OXIS International Names Former Wal-Mart Executive Ken Eaton to Board of Directors 2OXIS International Names Former Wal-Mart Executive Ken Eaton to Board of Directors 3Pacira Pharmaceuticals, Inc. Announces Inclusion in Russell 3000 Index 2Pacira Pharmaceuticals, Inc. Announces Inclusion in Russell 3000 Index 3
(Date:7/25/2014)... MEDICC announced diplomas went to 1,382 new MDs ... of Havana’s graduation ceremonies that also included graduates of ... 879 international graduates from 28 countries, 20 were ... and hundreds of parents packed the Cuban labor union ... President Ramón Machado Ventura and Minister of Health Roberto ...
(Date:7/25/2014)... the leading pan-European association representing medical oncology professionals, ... Data Protection Regulation [1] could make cancer research ... doctors and cancer patients. , The proposed wording ... patient consent, meaning that researchers would have to ... in order to consult their data or use ...
(Date:7/25/2014)... Mahendra Trivedi and his wife Dahryn ... is Power’ on Saturday, July 26, 2014. People from ... life transforming event as they will get a chance ... days are left for the commencement of this rare ... Masters™ Dahryn Trivedi (his wife) and Alice Branton will ...
(Date:7/25/2014)... 25, 2014 CMS recently has imposed ... for providing inadequate access to prescription drugs. Agency audits ... health and safety of beneficiaries in areas such as ... and CMS is taking quick and firm actions to ... Services webinar, “Avoiding Costly Part D Sanctions: Rx ...
(Date:7/25/2014)... Abilene, Texas (PRWEB) July 25, 2014 Yisrayl ... posted a new article on his blog explaining why so ... are needed the most. , In the article, Yisrayl ... going out and shares the results. For example, in one ... displayed all over church grounds to pray for rain; ironically, ...
Breaking Medicine News(10 mins):Health News:MEDICC Congratulates 20 New MDs for the USA Graduating from Cuba’s Latin American Medical School 2Health News:MEDICC Congratulates 20 New MDs for the USA Graduating from Cuba’s Latin American Medical School 3Health News:Is Europe putting cancer research at risk? 2Health News:Mahendra Trivedi to Host an Online Workshop ‘Consciousness is Power’ 2Health News:Mahendra Trivedi to Host an Online Workshop ‘Consciousness is Power’ 3Health News:Aug. 5 Webinar to Offer Strategies for Preventing Rx Access Issues and Avoiding Part D Sanctions 2Health News:Yisrayl Hawkins Says Prayers for Rain Result in Violent Hail Because Prayers Are Not Being Heard in New Post 2Health News:Yisrayl Hawkins Says Prayers for Rain Result in Violent Hail Because Prayers Are Not Being Heard in New Post 3
... Nov. 3 Rib-X Pharmaceuticals, Inc.,("Rib-X" or the ... development of novel antibiotics for the treatment of,antibiotic-resistant ... Chief Executive Officer, is scheduled to present at ... Monday, November 10,2008 at 2:00pm EST. The conference ...
... TSX: BMR, TORONTO, Nov. 3 /PRNewswire-FirstCall/ - ... development and,commercialization of cancer therapies, announced today that ... of the Company, will present a,corporate update at ... being held in New York City from November ...
... Most frequent tumor sites were cervix, head and neck, ... -- An estimated 25,000 cases of cancers associated with ... District of Columbia between 1998 and 2003, U.S. officials ... that includes more than 100 different types, more than ...
... study comparing cancer rates of liver transplant patients to ... recipients face increased risks of developing cancer, especially non-Hodgkin,s ... the first year of follow-up and among younger transplant ... of Liver Transplantation , a journal by John ...
... new studies conclude that a review which claimed that homeopathy ... was seriously flawed. , George Lewith, Professor of ... indication of which trials were analysed nor of the various ... scientific practice. If we presume that homeopathy works for some ...
... genetic vulnerability , , MONDAY, Nov. 3 (HealthDay News) ... States that get a lot of precipitation appear to ... study suggests. , Because these children may spend more ... atmosphere to the ground, they might be exposed to ...
Cached Medicine News:Health News:Rib-X Pharmaceuticals, Inc. to Present at the Rodman & Renshaw 10th Annual Healthcare Conference 2Health News:Bradmer to present at Rodman & Renshaw Healthcare Conference 2Health News:Bradmer to present at Rodman & Renshaw Healthcare Conference 3Health News:U.S. Reported 25,000 Cases of HPV-Related Cancers Annually 2Health News:Liver transplant recipients have higher cancer risk 2Health News:New evidence for homeopathy 2Health News:Rainier Spots Show Higher Autism Rates 2Health News:Rainier Spots Show Higher Autism Rates 3Health News:Rainier Spots Show Higher Autism Rates 4
... lens, doctors have to make a trade off ... Now, with the Digital Wide Field lens ... both in one lens. This lens provides ... non-contact lens paired with the higher magnification required ...
... The Stryker Wedge Suture Anchors are titanium ... and styles. The Wedge anchors are simple ... and OR staff. The following sizes and ... Suture, 5.0mm Single Eyelet 2 Sutures, 5.0mm ...
... Suture Anchor is a 3.0mm single loaded ... (PLLA). The anchor barb catches on the ... until it "breaks" free. The small size ... also frequently used in rotator cuff repair ...
... absorbable co-polymer synthesized from all-natural ingredients: ... acid. Unlike the homopolymers in common ... (PLLA) or 100% poly-glycolic acid (PGA), ... crystallinity), meaning that its degradation is ...
Medicine Products: